首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2858篇
  免费   136篇
  国内免费   92篇
耳鼻咽喉   13篇
儿科学   56篇
妇产科学   17篇
基础医学   395篇
口腔科学   19篇
临床医学   147篇
内科学   416篇
皮肤病学   25篇
神经病学   447篇
特种医学   84篇
外科学   130篇
综合类   247篇
预防医学   142篇
眼科学   14篇
药学   589篇
中国医学   95篇
肿瘤学   250篇
  2023年   35篇
  2022年   46篇
  2021年   50篇
  2020年   63篇
  2019年   65篇
  2018年   62篇
  2017年   59篇
  2016年   56篇
  2015年   62篇
  2014年   144篇
  2013年   157篇
  2012年   148篇
  2011年   170篇
  2010年   125篇
  2009年   147篇
  2008年   125篇
  2007年   114篇
  2006年   122篇
  2005年   102篇
  2004年   74篇
  2003年   90篇
  2002年   90篇
  2001年   75篇
  2000年   76篇
  1999年   45篇
  1998年   48篇
  1997年   50篇
  1996年   40篇
  1995年   37篇
  1994年   32篇
  1993年   30篇
  1992年   29篇
  1991年   30篇
  1990年   37篇
  1989年   21篇
  1988年   32篇
  1987年   42篇
  1986年   31篇
  1985年   69篇
  1984年   44篇
  1983年   28篇
  1982年   35篇
  1981年   29篇
  1980年   28篇
  1979年   21篇
  1978年   20篇
  1977年   11篇
  1974年   6篇
  1973年   7篇
  1972年   7篇
排序方式: 共有3086条查询结果,搜索用时 15 毫秒
1.
目的 研究异型增生程度不同的口腔白斑和不同分级的鳞癌中谷胱苷肽S转移酶π(GST π)的表达 ,探讨GST π在口腔鳞癌发生发展中的作用。 方法 采用免疫S -P法 ,对 5 4例轻、中、重度异型增生 ,4 7例高、中、低分化的口腔鳞癌 ,7例口腔粘膜上皮单纯增生患者组织进行GST π检测。 结果 口腔粘膜上皮单纯增生组织中未见GST π的表达 ,轻、中、重度异型增生病例中的GST π阳性率分别为4 7.8%、5 2 .9%和 6 4 .2 % ,高于单纯增生组 (P <0 .0 1) ;高分化鳞癌GST π阳性率为 6 4 .7% ,中、低分化鳞癌组分别为 2 8.5 %及 2 2 .2 % ,中、低分化鳞癌组表达均低于高分化鳞癌组及异型增生组 (P <0 .0 5 )。 结论 GST π表达的变化与口腔鳞癌早期的发生发展密切相关  相似文献   
2.
The immunohistochemical localization of manganese (Mn)-superoxide dismutase (Mn-SOD) was studied in the rat basal forebrain using polyclonal antibodies to Mn-SOD. Neurons of the basal forebrain exhibit a high density of Mn-SOD immunoreactivity. Double immunostaining with a monoclonal antibody to choline acetyltransferase demonstrated that both cholinergic and non-cholinergic neurons in the basal forebrain are intensely immunoreactive for Mn-SOD.  相似文献   
3.
In the present study, we examined the effect of intracerebroventricularly (i.c.v.) injected choline on both basal and stimulated oxytocin release in conscious rats. I.c.v. injection of choline (50–150 μg) caused time- and dose-dependent increases in plasma oxytocin levels under normal conditions. The increase in plasma oxytocin levels in response to i.c.v. choline (150 μg) was greatly attenuated by the pretreatment of rats with atropine (10 μg; i.c.v.), muscarinic receptor antagonist. Mecamylamine (50 μg; i.c.v.), a nicotinic receptor antagonist, failed to suppress the effect of 150 μg choline on oxytocin levels. Pretreatment of rats with 20 μg of hemicholinium-3 (HC-3), a specific inhibitor of choline uptake into nerve terminals, greatly attenuated the increase in plasma oxytocin levels in response to i.c.v. choline injection. Osmotic stimuli induced by either oral administration of 1 ml hypertonic saline (3 M) following 24-h dehydration of rats (type 1) or an i.c.v. injection of hypertonic saline (1 M) (type 2) increased plasma oxytocin levels significantly, but hemorrhage did not alter basal oxytocin concentrations. The i.c.v. injection of choline (50, 150 μg) under these conditions caused an additional and significant increase in plasma oxytocin concentrations beyond that produced by choline in normal conditions. These data show that choline can increase plasma oxytocin concentrations through the stimulation of central cholinergic muscarinic receptors by presynaptic mechanisms and enhance the stimulated oxytocin release.  相似文献   
4.
The in vitro capacity of sympathetic superior cervical ganglia (SCG) to take up [3H]choline from the extracellular medium, to synthesize acetylcholine from [3H]choline, and to release [3H]acetylcholine in response to a high K+ concentration, were examined in rats throughout a 24-h cycle. Both the release of [3H]acetylcholine and the synthesis of [3H]acetylcholine from [3H]choline exhibited significant diurnal variations, showing maxima during the first half of the night. After these maxima, nocturnal acetylcholine release and synthesis decayed to daytime levels and remained low until the end of the night. [3H]Choline uptake by rat SCG did not vary significantly throughout a 24-h period. A 1.5-h exposure of rats to darkness at the 5th hour of light phase of the daily photoperiod did not change significantly any parameter studied. A 20-min, 5-Hz, electrical stimulation of the preganglionic trunk of SCG excised from rats at noon increased significantly subsequent K+-induced [3H]acetylcholine release but did not change [3H]acetylcholine synthesis. In decentralized SCG of rats subjected to a unilateral SCG decentralization and a contralateral sham-operation 7 days earlier, [3H]acetylcholine release and synthesis were highly reduced or abolished at the decentralized side, while [3H]choline uptake remained unaltered. The present results suggest that an activation of preganglionic rat SCG neurons takes place during the first half of the scotophase.  相似文献   
5.
应用原位杂交技术,观察了二乙基亚硝胺(DEN)诱发大鼠肝癌前病变组织中胎盘型谷胱甘肽S转移酶(GST-P)mRNA的表达。结果显示,GST-PmRNA主要在癌前病变肝组织中的变异灶及灶外卵圆形细胞内表达,且在变异灶间或和同一灶内阳性细胞间表达程度不尽一致,而正常肝、再生肝组织中未见其表达。提示在分子水平上变异灶细胞及卵圆型细胞可能成为实验性肝癌的癌前期细胞  相似文献   
6.
重组O-GLcNAc糖基转移酶在昆虫细胞中的表达和纯化   总被引:1,自引:1,他引:0  
蛋白质的 O- Glc NAc糖基化修饰是一种细胞核蛋白与细胞浆蛋白的蛋白质翻译后修饰。不同于膜蛋白和分泌蛋白的糖基化修饰 ,与蛋白质磷酸化修饰相似。催化蛋白质 O- Glc NAc糖基转移酶 ( OGT)已被克隆。用Hi5昆虫细胞系统表达并纯化了具有活性的重组 OGT。在 Hi5昆虫细胞中表达的鼠肝 OGT带有一 His 6标记片段。经镍离子螯合柱纯化后 ,其比活性达到 0 .88nmol· min- 1·m g- 1 OGT。因此本研究为进一步研究蛋白 O- Glc NAc糖基化修饰提供重要资源  相似文献   
7.
糖尿病早期肾损害指标的探讨   总被引:1,自引:0,他引:1  
目的 探讨早期诊断糖尿病肾损害的方法。方法 采用免疫透射比浊法检测尿转铁蛋白 (TF)和尿微量白蛋白(mALB) ,速率法检测尿N 乙酰 B D 氨基葡萄糖苷酶 (NAG) ,Jaffe速率法测尿肌酐。结果 糖尿病患者尿蛋白定性阴性的尿TF、mALB、NAG均较对照组显著增高 (p <0 0 1) ,单项及双项检测TF、mALB、或NAG这三项指标阳性率偏低 ,联合三项检测阳性率可达 91 1%。结论 检测尿中TF、mALB、NAG是诊断糖尿病早期肾损害指标的敏感指标  相似文献   
8.
Retinol-binding protein (RBP) is the transport protein that carries retinol in the circulation from the liver to its target tissues. The existence of a cell-surface receptor on the target cells, which mediates the uptake of retinol from RBP, has been known since 1975. Recently, it was identified as an integral transmem-brane protein named STRA6 that is inducible by retinoic acid in certain cancer cells. The receptor was found to be highly specific for RBP, with high affinity, and to be localized in all tissues known to require retinol for their function, particularly the pigment epithelium of the eye.  相似文献   
9.
10.
[3H]hemicholinium-3 (HC-3) binding characteristics have been investigated using membrane binding assays and in vitro receptor autoradiography. In rat brain membrane preparations, [3H]HC-3 binds with high affinity to an apparent single class of sites. [3H]HC-3 binding is Na+-dependent. The ligand selectivity pattern strongly suggests that [3H]HC-3 selectivity labels the high affinity choline uptake (HACU) in brain membranes (HC-3 greater than choline greater than carbamylcholine greater than acetylcholine). This hypothesis is also supported by quantitative autoradiographic data which demonstrate that the discrete distribution of [3H]HC-3 binding sites correlates very well with the known distribution of other cholinergic markers such as choline acetyltransferase (ChAT), acetylcholinesterase (AChE), HACU, and [3H]AH-5183 (blocker of the vesicular transport of acetylcholine). For example, high densities of labelling are observed for these different markers in the interpeduncular nucleus, anteroventral nucleus of the thalamus, striatum, basolateral nucleus of the amygdala, and an exquisite laminar distribution in the hippocampus. Similar autoradiographic distributions of [3H]HC-3 binding sites are observed in other mammalian species such as guinea pig and monkey. Finally, 7-day unilateral kainic acid lesions of the nucleus basalis magnocellularis (nbm) decrease cortical [3H]HC-3 binding and ChAT activity, although not to a similar extent. In summary, these results demonstrate that [3H]HC-3 is a selective ligand of the HACU in mammalian brain. Thus, it is now possible to characterize precisely various structural components of the cholinergic synapses using markers such as [3H]HC-3, ChAT, HACU, [3H]AH-5183, and selective muscarinic and nicotinic receptor radioligands.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号